← Revolution Medicines, Inc. (RVMD) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Revolution Medicines, Inc. (RVMD)
Biological Products, (No Diagnostic Substances) · market cap $41.1B · as of 2026-07-09
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-04 (est.)
Earnings
Pipeline
5
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Revolution Medicines (RVMD) is a clinical-stage oncology company focused on RAS pathway inhibition, with a pipeline spanning multiple Phase 2 and Phase 3 programs targeting KRAS-driven cancers including NSCLC, colorectal cancer, and pancreatic cancer. The company reported two positive Phase 3 readouts in June 2026 and faces a near-term regulatory decision on daraxonrasib (NSCLC) by September 2026. A critical financial concern: reported cash of $440.9M against a stated runway of only 3.7 months as of July 2026, implying an urgent financing need.
The catalyst path
- 2026-11-04 (est.)Earningsimp 5/10
- 2027-06-15 (est.)Phase 2 · RMC-6291imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| daraxonrasib | Phase 3 | NSCLC (Non-small Cell Lung Cancer) |
| RMC-4630 | Phase 2 | Non-Small Cell Lung Cancer |
| RMC-6236 | Phase 3 | Colorectal Cancer |
| RMC-6291 | Phase 2 | Non-Small Cell Lung Cancer, NSCLC |
| Cobimetinib | Phase 2 | Solid Tumor |
Price & technical context
3-month
+8.8%
6-month
+108.7%
12-month
+340.9%
52-wk range
$45.70–$221.15
vs 50-day MA
+1.9%
vs 200-day MA
+41.7%
Realized vol
60.8%
Max drawdown
-48.6%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for RVMD (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.